Stock Market Reviews

VTRS (Viatris Inc.) News

Get the latest news, insights, and market updates on VTRS (Viatris Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
  Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third quarter of 2025.
  Nov 10, 2025 - $VTRS
• How Upgraded Guidance and Capital Returns at Viatris (VTRS) Have Changed Its Investment Story
  Viatris Inc. recently reported strong third quarter 2025 results, raising its full-year guidance to US$13.9–14.3 billion in revenue and increasing anticipated adjusted earnings per share, supported by contributions from new products and the acquisition of Aculys Pharma. Management emphasized its ongoing pursuit of growth-focused mergers and acquisitions, while also reaffirming a commitment to shareholder returns through dividends and share repurchases exceeding US$920 million...
  Nov 8, 2025 - $VTRS
• Viatris’s (NASDAQ:VTRS) Q3 Sales Top Estimates
  Medication company Viatris (NASDAQ:VTRS) beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on year at $3.76 billion. The company’s full-year revenue guidance of $14.1 billion at the midpoint came in 1.2% above analysts’ estimates. Its non-GAAP profit of $0.67 per share was 8.5% above analysts’ consensus estimates.
  Nov 6, 2025 - $VTRS
• Viatris: Q3 Earnings Snapshot
  CANONSBURG, Pa. AP) — Viatris Inc (VTRS) on Thursday reported a loss of $128.2 million in its third quarter. On a per-share basis, the Canonsburg, Pennsylvania-based company said it had a loss of 11 cents.
  Nov 6, 2025 - $VTRS
• Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates
  Viatris (VTRS) delivered earnings and revenue surprises of +6.35% and +3.09%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 6, 2025 - $VTRS
• Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance
  Viatris tops Q3 earnings and revenue estimates, lifts 2025 outlook, and expands its Japan presence with Aculys Pharma deal.
  Nov 6, 2025 - $VTRS
• Viatris (VTRS) Reports Q3 Earnings: What Key Metrics Have to Say
  The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
  Nov 6, 2025 - $VTRS
• Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance
  Viatris Inc. (Nasdaq: VTRS) today reported strong third quarter 2025 financial results and updated full-year financial guidance.
  Nov 6, 2025 - $VTRS
• Needle-Free Devices, Technologies and Global Markets (2025-2030) Featuring Profiles of GSK, Novartis, Viatris, PharmaJet and Other Key Players
  Key market opportunities for needle-free devices lie in technological advancements, regional expansion across Asia-Pacific and MEA, and growing applications in vaccines, pain management, and insulin delivery. Strategic alliances and innovations from major players like GSK and Novartis can further drive growth. Global Needle-Free Devices Market Global Needle-Free Devices Market Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "Needle-Free Devices: Technologies and Global Markets" has been added to R
  Nov 6, 2025 - $VTRS
• Viatris (VTRS) Q3 2025 Earnings Call Transcript
  Scott Andrew Smith: We delivered another strong quarter by focusing on our 2025 strategic priorities. Driving strong commercial execution, advancing our pipeline, returning capital to shareholders through dividends and share repurchases, pursuing end-market business development opportunities, and advancing our enterprise-wide strategic review to identify opportunities to deliver meaningful net cost savings.
  Nov 6, 2025 - $VTRS